MediProPharma, Inc., a Salt Lake City, UT-based pharmaceutical product development company, has raised un undisclosed sum of equity financing from local angel investment group Salt Lake Life Science Angels (SLLSA).
SLLSA was joined in the funding round by investors from the Sierra Angels, Olympus Angels, Utah Angels, Kickstart Seed Fund, and individual investors.
MediProPharma identifies and develops multifunctional, mechanism-based central nervous system (CNS) drugs. The company is currently advancing three drug development programs to commercial viability.
The therapeutic indications include Down syndrome, Alzheimer’s disease, brain injury, epilepsy, depression, and pain. The lead compound, a clinically validated cognitive enhancer, is now in pre-clinical development for the treatment of neurodegenerative diseases and disorders.